WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsEverpure, Inc. (P)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 676% more annual revenue ($28.43B vs $3.66B). P leads profitability with a 5.1% profit margin vs 4.1%. MDLN trades at a lower P/E of 31.3x. P earns a higher WallStSmart Score of 55/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 6.3Quality: 6.8
Piotroski: 4/9

P

Buy

55

out of 100

Grade: C-

Growth: 8.0Profit: 4.0Value: 3.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+68.8%)

Margin of Safety

+68.8%

Fair Value

$144.24

Current Price

$45.32

$98.92 discount

UndervaluedFair: $144.24Overvalued

Intrinsic value data unavailable for P.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN1 strengths · Avg: 10.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

P2 strengths · Avg: 9.0/10
EPS GrowthGrowth
139.7%10/10

Earnings expanding 139.7% YoY

Revenue GrowthGrowth
20.4%8/10

Revenue surging 20.4% year-over-year

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
31.3x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

P4 concerns · Avg: 3.3/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

Price/BookValuation
17.0x4/10

Trading at 17.0x book value

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

P/E RatioValuation
130.2x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth. Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : P

The strongest argument for P centers on EPS Growth, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : P

The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 130.2x leaves little room for execution misses.

Key Dynamics to Monitor

MDLN profiles as a value stock while P is a growth play — different risk/reward profiles.

P is growing revenue faster at 20.4% — sustainability is the question.

P generates stronger free cash flow (201M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

P scores higher overall (55/100 vs 52/100) and 20.4% revenue growth. MDLN offers better value entry with a 68.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Everpure, Inc.

TECHNOLOGY · COMPUTER HARDWARE · USA

Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.

Want to dig deeper into these stocks?